StockNews.AI
GILD
StockNews.AI
203 days

Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025

1. Gilead will release Q4 and FY 2024 results on February 11, 2025. 2. Management will host a webcast at 4:30 PM ET on reporting day. 3. The company develops medicines for diseases like COVID-19 and cancer. 4. Gilead operates in over 35 countries, enhancing global medical reach. 5. Financial results will include guidance for 2025, influencing investor sentiment.

5m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results and guidance can positively impact investor confidence.

How important is it?

Financial disclosures can significantly affect stock performance and market perception.

Why Short Term?

Immediate impact expected around the earnings release date.

Related Companies

GILD

Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025

FOSTER CITY, Calif.--()--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 guidance will be released on Tuesday, February 11, 2025, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s fourth quarter and full year 2024 financial results and provide a business update.

A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contacts

Jacquie Ross, CFA – Investors
investor_relations@gilead.com

Related News